IP Library Granted Patent US 11,628,205
Granted Patent B2
US 11,628,205 · App. 16/319,759 · Granted Apr 18, 2023

Conjugates of a factor VIII moiety having an oxime-containing linkage

Inventors: Mary J. Bossard (Madison, AL); Dawei Sheng (Fremont, CA)
Assignee: Nektar Therapeutics
A61K38/37A61K47/54A61K47/60C08G65/3314C08G65/3322C08G65/33306C08G65/33351C08G65/33396
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,628,205
App. No.
16/319,759
Granted
Apr 18, 2023
Kind
B2
Abstract

The present disclosure provides conjugates comprising a Factor VIII moiety covalently attached via an oxime-containing linkage to a water-soluble polymer, such as for example, a polyethylene glycol polymer. Methods for preparing and for administering such conjugates, are also provided, as are water-soluble polymer oxyamine reagents useful for preparing the subject conjugates, among other things.

Claims (9)

1. A conjugate comprising a branched poly(ethylene glycol) polymer covalently attached via an oxime-containing linkage to a carbohydrate of a Factor VIII moiety, the conjugate having a structure selected from:

where (m′) or (n) for each of the branched structures above independently ranges from about 1 to about 4,000, X is a spacer comprising a chain of atoms and having an atom chain length of from 5 to 25 atoms, where at least one of the atoms is a heteroatom selected from 0, S, and NH, and FVIII is a glycosylated Factor VIII moiety comprising carbohydrate groups, where ˜CH-FVIII is a residue of a carbonyl group of an oxidized carbohydrate on the Factor VIII moiety.

2. The conjugate of claim 1 , wherein each (m′) or (n) is about 227.

3. The conjugate of claim 1 , wherein the Factor VIII moiety is glycosylated human recombinant B-domain deleted Factor VIII.

4. The conjugate of claim 1 , wherein the Factor VIII moiety is glycosylated human recombinant full length Factor VIII.

5. A composition comprising a conjugate of claim 1 and a pharmaceutically acceptable excipient.

6. A composition comprising a conjugate having a structure according to claim 1 , wherein the average degree of PEGylation for conjugates comprised in the composition is in a range from 1 to 3.5.

7. The conjugate of claim 1 , wherein the weight average molecular weight of the branched poly(ethylene glycol) polymer ranges from greater than 5,000 Daltons to 100,000 Daltons.

8. The conjugate of claim 1 , wherein the branched poly(ethylene glycol) polymer has a weight-average molecular weight between 2,000 Daltons and 85,000 Daltons.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2022
From: BOSSARD, MARY J.; SHENG, DAWEI
To: NEKTAR THERAPEUTICS
Reel/Frame 059457/0989 →
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
SECURITY INTEREST Recorded Apr 11, 2019
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 048859/0669 →